Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

0.57 EUR

-8.23 %

5,661 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

-8.23 %
-70.33 %
-72.64 %
-71.55 %
-73.96 %
-72.90 %
-84.54 %
-84.45 %
-83.65 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
67.98M EUR
Turnover
327.43K EUR
P/E (adj.) (26e)
-5.42
EV/EBIT (adj.) (26e)
-5.92
P/B (26e)
19.23
EV/S (26e)
28,142.86
Dividend yield-% (26e)
-
Coverage
Recommendation
Reduce
Target price
0.65 EUR
Updated
2026-03-05
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-05

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30/3
2026

General meeting '26

26/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I don’t think they forgot the AGM notice or the announcement regarding the postponement. There might be some plans underway related to financing arrangements—possibly something more than just a share issue—and the board waited until the last minute before announcing the postponement...
5 hours ago
by jukkamu
8
Partnering with Mid-Pharma for HR MDS would be an excellent move right now. The problem has likely been that Big Pharma is more interested in solid tumors, for which Faron doesn’t have sufficient evidence yet. Partnering with a Mid-Pharma would also solve the issue where Big Pharma...
4 hours ago
by Mestarihiihtäjä
6
These are really exciting times. Will there be a share issue or not, will a potential partnership with new Phase II/III trial plans happen or not. Otherwise, what are your thoughts on the big picture—does it even make sense to partner with a Mid-Pharma for HR MDS?
5 hours ago
3
True. A notice just came out that the meeting is scheduled to be held on May 4th instead of the previously planned March 30th.
6 hours ago
3
Well, Bex selling more than double compared to the top drug Keytruda in 3-5 years. Impossible even if Merck bought Bex tomorrow and started 10 phase 3 trials ASAP.
2 hours ago
by Clark kent
2
This is a quite sensitive topic for Inderes, easily flagged or otherwise removed, but these matters must be allowed to be brought to light within the framework of Finnish law. I am not blaming anyone, but I am issuing a challenge. Antti, have you considered that if Bex were suitable...
3 hours ago
2
In January 2025, you were also holding an analyst accountable for their estimates here. At that time, you said you didn’t see partnering priced into the current share price, “which is almost a hundred percent certain for this year, or the sale of the whole outfit.” In your view, ...
2 hours ago
by JuhaR
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.